Core Points - Idorsia Ltd has announced the results of its repurchase offer for outstanding convertible bonds totaling CHF 204 million maturing in 2025 and CHF 600 million maturing in 2028 [1][2] - The repurchase offer for the 2025 bonds saw an acceptance rate of 91.90%, with bondholders accepting an aggregate nominal value of CHF 187,476,000, while the 2028 bonds had a 94.53% acceptance rate with CHF 567,200,000 accepted [2] - The settlement of the repurchase offer is expected to occur on August 26, 2025, pending the satisfaction or waiver of certain conditions [3] Company Overview - Idorsia aims to challenge established medical paradigms by discovering, developing, and commercializing transformative medicines, evolving into a leading biopharmaceutical company [5] - The company is headquartered near Basel, Switzerland, and has a strong focus on small-molecule drugs, with a promising in-house development pipeline and partnerships to enhance portfolio value [6]

Core Viewpoint - Idorsia Ltd has successfully completed a repurchase offer for its convertible bonds, with significant acceptance rates from bondholders for both the 2025 and 2028 bonds [1][2]. Group 1: Repurchase Offer Details - The repurchase offer was launched on June 25, 2025, for CHF 204 million convertible bonds maturing in 2025 and CHF 600 million convertible bonds maturing in 2028 [1]. - As of the end of the additional acceptance period, bondholders accepted the repurchase offer for the CB 2025 with an aggregate nominal value of CHF 187,476,000, which is 91.90% of the total issued nominal value [2]. - For the CB 2028, bondholders accepted the offer with an aggregate nominal value of CHF 567,200,000, corresponding to 94.53% of the total issued nominal value [2]. Group 2: Settlement and Documentation - The settlement of the repurchase offer is expected to occur on August 26, 2025, pending the satisfaction or waiver of certain offer conditions [3]. - Additional information regarding the repurchase offer and related documentation can be found on Idorsia's official website [3]. Group 3: Company Overview - Idorsia aims to challenge accepted medical paradigms by discovering, developing, and commercializing transformative medicines, positioning itself as a leading biopharmaceutical company [5]. - The company is headquartered near Basel, Switzerland, and has a strong focus on small-molecule drugs that can change treatment paradigms for various patients [6].